Fig. 1

Proportion of MSC in clinical samples correlates with Imatinib resistance and prognosis. Paired samples are drug-sensitive and subsequently drug-resistant surgical samples from the same individual. Immunofluorescence assay for CD73 and CD90 in paired comparative clinical samples (A). The relative fluorescence intensity of CD73 or CD90 was significantly enhanced in the drug-resistant group compared to the drug-sensitive group (B). The proportion of MSC obtained using the FACS method in the other 50 samples was significantly correlated with progression-free survival (C). Overall survival curve analysis was performed by grouping all cases using the median of the proportion of MSC in the 50 samples as the threshold. The proportion of MSC in the tumour tissue was significantly correlated with the overall survival of the patients. The selected threshold is determined to be 1X median, as the data dispersion is minimal and no outliers were detected. Median-1.71% (D). Density plot of MSC proportions, The horizontal axis of the graph denotes the MSC proportion across the 50 cases, whereas the vertical axis indicates the probability of occurrence associated with each data point. (E) The density plot of the proportion of MSCs amongst 50 cases is graphically represented. The horizontal axis denotes the proportion of MSCs while the vertical axis indicates the frequency of occurrence of each respective proportion. Data are means ± SEM *p < 0.05; **p < 0.01